NASDAQ:RWLK - Rewalk Robotics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.2404 -0.01 (-3.99 %) (As of 01/20/2019 04:00 PM ET)Previous Close$0.2404Today's Range$0.2380 - $0.285052-Week Range$0.16 - $1.35Volume18.91 million shsAverage Volume4.70 million shsMarket Capitalization$8.60 millionP/E Ratio-0.24Dividend YieldN/ABeta0.81 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes exoskeletons for wheelchair-bound individuals with mobility impairments or other medical conditions. The company offers ReWalk Personal for everyday use to paraplegic individuals at home and in their communities; and ReWalk Rehabilitation for exercise and therapy used in hospitals and rehabilitation centers in the United States and Europe. It is also developing ReWalk Restore, a soft suit exoskeleton for individuals who have suffered a stroke. ReWalk Robotics Ltd. markets and sells its products directly to third party payers, institutions and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was founded in 2001 and is headquartered in Yokne'am Illit, Israel. Receive RWLK News and Ratings via Email Sign-up to receive the latest news and ratings for RWLK and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical appliances & supplies Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RWLK Previous Symbol CUSIPN/A Webwww.rewalk.com Phone972-4959-0123Debt Debt-to-Equity RatioN/A Current Ratio0.91 Quick Ratio0.69Price-To-Earnings Trailing P/E Ratio-0.24 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$7.75 million Price / Sales1.11 Cash FlowN/A Price / Cash FlowN/A Book Value$0.13 per share Price / Book1.85Profitability EPS (Most Recent Fiscal Year)($0.99) Net Income$-24,710,000.00 Net Margins-352.11% Return on Equity-3,654.32% Return on Assets-119.11%Miscellaneous Employees65 Outstanding Shares35,780,000Market Cap$8.60 million OptionableNot Optionable Rewalk Robotics (NASDAQ:RWLK) Frequently Asked Questions What is Rewalk Robotics' stock symbol? Rewalk Robotics trades on the NASDAQ under the ticker symbol "RWLK." How were Rewalk Robotics' earnings last quarter? Rewalk Robotics Ltd (NASDAQ:RWLK) posted its quarterly earnings data on Thursday, November, 8th. The medical device company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.01. The medical device company earned $1.62 million during the quarter, compared to analysts' expectations of $2.12 million. Rewalk Robotics had a negative return on equity of 3,654.32% and a negative net margin of 352.11%. View Rewalk Robotics' Earnings History. When is Rewalk Robotics' next earnings date? Rewalk Robotics is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for Rewalk Robotics. What guidance has Rewalk Robotics issued on next quarter's earnings? Rewalk Robotics issued an update on its FY 2018 earnings guidance on Thursday, November, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $7-8 million, compared to the consensus revenue estimate of $8.21 million. What price target have analysts set for RWLK? 3 Wall Street analysts have issued 1 year price objectives for Rewalk Robotics' shares. Their forecasts range from $1.00 to $2.00. On average, they anticipate Rewalk Robotics' stock price to reach $1.6667 in the next year. This suggests a possible upside of 593.3% from the stock's current price. View Analyst Price Targets for Rewalk Robotics. What is the consensus analysts' recommendation for Rewalk Robotics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rewalk Robotics in the last year. There are currently 1 sell rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Rewalk Robotics. What are Wall Street analysts saying about Rewalk Robotics stock? Here are some recent quotes from research analysts about Rewalk Robotics stock: 1. According to Zacks Investment Research, "ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury. The Company's exoskeletons allow wheelchair-bound individuals with mobility impairments or other medical conditions the ability to stand and walk once again. It offers ReWalk Personal for everyday use to individuals at home and in their communities; and ReWalk Rehabilitation for exercise and therapy to individuals with lower limb disabilities in the clinical rehabilitation environment. ReWalk Robotics Ltd. is headquartered in Yokneam Ilit, Israel. " (10/25/2018) 2. Canaccord Genuity analysts commented, "We maintain our BUY rating on ReWalk Robotics following Q4/17 results. ReWalk reported revenues of $1.5M, below CG/consensus of $2.1M/$1.9M. Although the shipment of 23 systems was well below our expectation for 42 systems, ReWalk sales benefited from a favorable mix of system purchases and rental conversions in the quarter. Despite the weaker than anticipated system placements, we were encouraged to see another quarter of strong demand and another positive coverage decision with reimbursement through Italy’s worker’s compensation group. While commercial unit placements continue to be lumpy Q/Q we continue to view the broader pipeline (Restore soft suit for stroke) positively in the H2/18 and beyond. Positive momentum in demand and reimbursement decisions: In Q4/17 the company placed 23 total units, down from 39 Y/Y but up Q/Q from 16." (3/12/2018) Has Rewalk Robotics been receiving favorable news coverage? News coverage about RWLK stock has trended neutral on Sunday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Rewalk Robotics earned a news impact score of 0.1 on InfoTrie's scale. They also assigned press coverage about the medical device company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term. Are investors shorting Rewalk Robotics? Rewalk Robotics saw a decline in short interest in the month of December. As of December 31st, there was short interest totalling 549,386 shares, a decline of 44.7% from the December 14th total of 993,726 shares. Based on an average daily volume of 2,210,903 shares, the short-interest ratio is presently 0.2 days. Currently, 1.2% of the shares of the stock are sold short. View Rewalk Robotics' Current Options Chain. Who are some of Rewalk Robotics' key competitors? Some companies that are related to Rewalk Robotics include Bionik Laboratories (BNKL), COLLPLANT HOLDI/S (CLGN), NanoVibronix (NAOV), Precision Therapeutics (AIPT), Histogenics (HSGX), Wound Management Technologies (WNDM), Allied Healthcare Products (AHPI), Avitar (AVTI) and Halyard Health (HYH). Who are Rewalk Robotics' key executives? Rewalk Robotics' management team includes the folowing people: Mr. Lawrence J. Jasinski, CEO & Director (Age 62)Mr. Ofir Koren, GM and VP of Research, Devel. & Regulatory (Age 49)Mr. Ori Gon, Chief Financial Officer (Age 37)Ms. Miri Pariente, VP of QA & Operations (Age 42)Mr. Loren Wass, VP of Sales & Reimbursement How do I buy shares of Rewalk Robotics? Shares of RWLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Rewalk Robotics' stock price today? One share of RWLK stock can currently be purchased for approximately $0.2404. How big of a company is Rewalk Robotics? Rewalk Robotics has a market capitalization of $8.60 million and generates $7.75 million in revenue each year. The medical device company earns $-24,710,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis. Rewalk Robotics employs 65 workers across the globe. What is Rewalk Robotics' official website? The official website for Rewalk Robotics is http://www.rewalk.com. How can I contact Rewalk Robotics? Rewalk Robotics' mailing address is 3 Hatnufa Street Floor 6, Yokneam Ilit L3, 2069203. The medical device company can be reached via phone at 972-4959-0123. MarketBeat Community Rating for Rewalk Robotics (NASDAQ RWLK)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 214 (Vote Outperform)Underperform Votes: 215 (Vote Underperform)Total Votes: 429MarketBeat's community ratings are surveys of what our community members think about Rewalk Robotics and other stocks. Vote "Outperform" if you believe RWLK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RWLK will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/20/2019 by MarketBeat.com StaffFeatured Article: What is net income?